Cargando…
Long-term safety and efficacy of natalizumab in relapsing-remitting multiple sclerosis: impact on quality of life
Natalizumab was the first monoclonal antibody to be approved for the treatment of relapsing-remitting multiple sclerosis (RRMS) based on its short-term efficacy and overall tolerability. However, the incidence of treatment-associated progressive multifocal leukoencephalopathy (PML), an infection of...
| Autores principales: | , , |
|---|---|
| Formato: | Online Artículo Texto |
| Lenguaje: | English |
| Publicado: |
Dove Medical Press
2014
|
| Materias: | |
| Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3983075/ https://www.ncbi.nlm.nih.gov/pubmed/24741337 http://dx.doi.org/10.2147/PROM.S41768 |